Fexofenadine decreases sensitivity to and montelukast improves recovery from inhaled mannitol.
about
Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and childrenAnti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and childrenAddition of anti-leukotriene agents to inhaled corticosteroids for chronic asthmaThe safety and efficacy of inhaled dry powder mannitol as a bronchial provocation test for airway hyperresponsiveness: a phase 3 comparison study with hypertonic (4.5%) saline'Indirect' challenges from science to clinical practicePulmonary gas exchange response to exercise- and mannitol-induced bronchoconstriction in mild asthmaThe effects of histamine and leukotriene receptor antagonism on nasal mannitol challenge in allergic rhinitis.Pulmonary function assessment in the early phase of patients with smoke inhalation injury from fireAnti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma.An open-label study examining the effect of pharmacological treatment on mannitol- and exercise-induced airway hyperresponsiveness in asthmatic children and adolescents with exercise-induced bronchoconstriction.Addition of anti-leukotriene agents to inhaled corticosteroids for chronic asthma.Second-generation antihistamines in asthma therapy: is there a protective effect?Asthma, airway biology, and nasal disorders in AJRCCM 2001.Cysteinyl leukotriene antagonism inhibits bronchoconstriction in response to hypertonic saline inhalation in asthma.The effect of omega-3 fatty acids on bronchial hyperresponsiveness, sputum eosinophilia, and mast cell mediators in asthma.Adenosine monophosphate bronchial provocation and the actions of asthma therapy.Cough response to isocapnic hyperpnoea of dry air and hypertonic saline are interrelated.Science and physicianly practice: are they compatible?Does bronchial hyperresponsiveness in asthma matter?Single-dose agents in the prevention of exercise-induced asthma: a descriptive review.Indirect bronchial hyper-responsiveness: the coming of age of a specific group of bronchial challenges.Inflammatory basis of exercise-induced bronchoconstrictionNon-invasive measurement of airway inflammation in asthma.Use of mannitol inhalation challenge in assessment of cough.Fexofenadine hydrochloride in the treatment of allergic disease: a reviewThe use of inhaled mannitol in the diagnosis and management of asthma.The usefulness of the mannitol challenge test for asthma.Nonpulmonary influences on gas exchange.Airway hyperresponsiveness in asthma: mechanisms, clinical significance, and treatment.Sodium cromoglycate alone and in combination with montelukast on the airway response to mannitol in asthmatic subjects.Exercise-induced wheeze: Fraction of exhaled nitric oxide-directed management.Airway response to mannitol challenge in asthmatic children using impulse oscillometry.Budesonide reduces sensitivity and reactivity to inhaled mannitol in asthmatic subjects.Effects of mediator antagonism on mannitol and adenosine monophosphate challenges.Relationship between airway hyperresponsiveness to mannitol and adenosine monophosphate.Bronchial provocation testing with dry powder mannitol in children with cystic fibrosis.Influence of air flow on the performance of a dry powder inhaler using computational and experimental analyses.ALOX5 promoter genotype, asthma severity and LTC production by eosinophils.The occurrence of refractoriness and mast cell mediator release following mannitol-induced bronchoconstriction.Release of prostaglandin D2 and leukotriene C4 in response to hyperosmolar stimulation of mast cells.
P2860
Q24197682-70D65011-EBB2-4B8E-8C6D-0BEC1AB20033Q24247433-5403C055-484D-48A5-B9DD-2BE5327ADCA8Q24247489-988F9F75-761D-46EB-890E-2EFD4D7DF0DDQ25255964-75D5EDFD-CA61-4545-ACA1-5A00C610A50DQ26767035-94AD2791-6BC2-4406-98AF-7F00AB1CF388Q28292353-AA42E810-906E-40A6-A3A4-59B3D2E0F040Q30498416-FE9BE5FA-4A5B-455F-9624-0255BEA80681Q33814686-7C600CD2-3B1E-4969-BC78-97F7312D82C4Q33978718-6A738083-5D76-418E-9635-62FB3C17E252Q34062204-0EC4C93F-487D-4313-B954-F2FEA9E4B620Q34424227-EBFF3529-C946-46D9-BEC4-99ECD06EBC89Q34544512-9EADB3F3-1834-4E93-89B1-BD0AC90D17AFQ34550135-94A5105F-ACEC-4801-A6C1-1C975FC5EBFAQ34823193-382F17AC-EE6F-4C72-85E8-9C1AF0EDF11DQ35041503-E9F409C7-26C2-4584-91CE-389396AA1AC3Q35076739-E0A8F464-AF6A-43BE-B6C1-00675F38C505Q35486830-F464C42C-ABD2-487A-A6C3-D26FDD64FCAFQ35608856-F6FD44BE-FBE5-4676-9F55-05B70B1DC2D1Q35839483-BE3C09D3-618E-462D-8B33-39FC7B9DEF42Q36013683-7EE7E5C4-463E-4755-91A3-D9C913A2E030Q36077352-EA15281B-F66A-4D88-95FC-3C3B418D501CQ36091759-73BF4093-EF1B-42CE-9A22-1005229C21C3Q36585609-3B68E3D2-8DF4-4938-9056-08A3792C7ED2Q37598048-10252B9F-3794-4654-AF40-41E44C5FEAC9Q37857671-F21A53FD-BB32-4F94-8BDC-10022FC99D84Q37961198-3975A0A2-B440-42BD-8F35-78045AC836D1Q38162254-D9C5F554-6E4D-45B7-A341-2F9A4C02EE92Q38271906-3466259E-5E73-4DE4-A4C2-674AE67DBC2EQ42401081-6AF2FFE0-5789-4FCD-8C41-C3345EB3319BQ43042740-D7B59FC6-C10A-4E3A-9FE8-1ACB7EFBA35EQ43118743-4E6FF72B-374F-4C5B-850B-351615A80075Q43297956-F5401E90-D9F8-4D52-A2BD-08D89EB877EFQ43919326-02189C5D-B250-4BEF-9333-95CF1A53DBB7Q44474627-A6DC4170-2586-4D4C-BC45-6FD6194F27F5Q44512151-4B62E6BC-AE5B-4C74-9604-2DB4085900B0Q46274587-90E5D3A9-2DFE-4076-99D3-58B21B943FA9Q46678370-BDE085E5-347A-4A8D-9E82-9ED5502BAF01Q46858446-F9314C24-E7FE-4290-A474-ABF4902E4008Q53273655-5EC460C9-67E7-4725-95A7-8F12F07C7BB0Q53590812-B1B76A95-9B3D-48B0-BEED-0B0A7EF3E8CC
P2860
Fexofenadine decreases sensitivity to and montelukast improves recovery from inhaled mannitol.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Fexofenadine decreases sensiti ...... ecovery from inhaled mannitol.
@en
Fexofenadine decreases sensiti ...... ecovery from inhaled mannitol.
@nl
type
label
Fexofenadine decreases sensiti ...... ecovery from inhaled mannitol.
@en
Fexofenadine decreases sensiti ...... ecovery from inhaled mannitol.
@nl
prefLabel
Fexofenadine decreases sensiti ...... ecovery from inhaled mannitol.
@en
Fexofenadine decreases sensiti ...... ecovery from inhaled mannitol.
@nl
P2093
P2860
P1476
Fexofenadine decreases sensiti ...... ecovery from inhaled mannitol.
@en
P2093
P2860
P304
P356
10.1164/AJRCCM.163.6.2006019
P407
P577
2001-05-01T00:00:00Z